Tessa Therapeutics, an international clinical stage biopharmaceutical company focusing on cellular immunotherapy treatments for cancer, has named Goran Ando as its new independent director, it was reported yesterday.
Ando was the former Chairman of Novo Nordisk A/S.
Dr. Ando brings more than 35 years of international healthcare experience to Tessa Therapeutics. Starting his career at Pfizer, he held senior positions at global healthcare and pharmaceutical businesses including Bristol-Myers Squibb and GlaxoSmithKline, before joining Pharmacia AB as Executive VP and then as Deputy CEO in 1995. More recently, he served as the chief executive officer of Cell Tech Group PLC and has been a senior adviser to leading specialist healthcare investment group, Essex Woodlands, since 2007. Until March 2018, he had been a member of the of Novo Holdings A/S board of directors.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer